Oakland, CA, United States
Oakland, CA, United States

Bartholomew JoJo "Bart" Simpson is a fictional character in the animated television series The Simpsons and part of the Simpson family. He is voiced by actress Nancy Cartwright and first appeared on television in The Tracey Ullman Show short "Good Night" on April 19, 1987. Bart was created and designed by cartoonist Matt Groening while he was waiting in the lobby of James L. Brooks' office. Groening had been called to pitch a series of shorts based on Life in Hell but instead decided to create a new set of characters. While the rest of the characters were named after Groening's family members, Bart's name was an anagram of the word brat. After appearing on The Tracey Ullman Show for three years, the Simpson family received its own series on Fox, which debuted December 17, 1989.At ten years old, Bart is the eldest child and only son of Homer and Marge, and the brother of Lisa and Maggie. His birth date is formally stated in season 26 episode "Simpsorama" as February 23 but this date is contradicted in earlier episodes. Bart's most prominent character traits are his mischievousness, rebelliousness and disrespect for authority. He has appeared in other media relating to The Simpsons, including video games, The Simpsons Movie, The Simpsons Ride, commercials, and comic books; he has also inspired an entire line of merchandise. In casting, Nancy Cartwright originally planned to audition for the role of Lisa, while Yeardley Smith tried out for Bart. Smith's voice was too high for a boy, so she was given the role of Lisa. Cartwright found that Lisa was not interesting at the time, so instead auditioned for Bart, which she thought was a better role. Hallmarks of the character include his chalkboard gags in the opening sequence; his prank calls to Moe; and his catchphrases "Eat my shorts", "¡Ay, caramba!", and "Don't have a cow, man!"During the first two seasons of The Simpsons , Bart was the show's breakout character and "Bartmania" ensued. Bart Simpson T-shirts sporting various slogans and catchphrases became popular, selling at a rate of a million per day at their peak. The song "Do the Bartman" became a number one charting single and the seventh best-selling song of 1991 in the United Kingdom. Bart's rebellious attitude and pride at underachieving caused many parents and educators to cast him as a bad role model for children. A T-shirt reading "I'm Bart Simpson. Who the hell are you?" was banned in several public schools. Around the third season, the series started to focus more on the family as a group, although Bart remains one of the most prominent characters on the series. Time named Bart one of the 100 most important people of the 20th century, and he was named "entertainer of the year" in 1990 by Entertainment Weekly. Nancy Cartwright has won several awards for voicing Bart, including a Primetime Emmy Award in 1992 and an Annie Award in 1995. In 2000, Bart, along with the rest of his family, was awarded a star on the Hollywood Walk of Fame. Wikipedia.

SEARCH FILTERS
Time filter
Source Type

Patent
Bart | Date: 2017-04-26

The present invention relates to a method for processing potatoes, comprising the provision of potatoes and the possible removal of the skin from said potatoes before further processing of the potatoes takes place. In this method potatoes are visually monitored for defects and then subdivided into good and bad potatoes, after which the bad potatoes are separated and additionally treated to selectively remove defective elements such as wireworms, rust, blackening, scab and eyes.


Patent
Bart and Bellon | Date: 2017-01-04

A modular device for wireless communication between a transmitter and a receiver, the latter being mounted on a fastener to be worn by an animal/a human being or to be in contact therewith, comprising a string of individual separate elements or modules (210, 310), each containing at least either the PCB (213, 313), the battery (214, 314) or one or more contact points (220, 320) of same polarity respectively, said separate individual elements (210, 310) being attached to one another thanks to at least two substantially parallel flexible tubes (31, 32 ; 331, 332) containing said wires, so that the specific location of the modules (220, 320) containing the contact points and the order or sequence thereof in the string define an extension length for the contact points.


The invention relates to a spiral pump and a device for treating water comprising this spiral pump, and associated method. The spiral pump comprises:- a housing provided with an inlet (8a, 8b, 8c) for water; and- a pump body (2) which is accommodated in the housing and rotatable around an axis (12), wherein the pump body (2) comprises at least one spiral channel,wherein a first outer end (8a, 8b, 8c) of the at least one spiral channel is located on an outer side of the pump body and forms an entrance opening for alternately taking in water and air through rotation of the pump body in the housing, and a second outer end of the at least one spiral channel debouches into an outlet (10) close to the axis, wherein the housing is embodied as pressure chamber.


The invention relates to a drum filter for water filtration and method therefor. The drum filter comprises: a housing; a filter drum arranged in the housing and comprising a filter surface, wherein the filter drum is rotatable around a shaft; an inlet for supplying water for filtering to an outward facing side of the filter surface for the purpose of collecting fouling on the filter surface; an outlet for discharging filtered water; and a sprayer for spraying clean the filter surface, wherein the sprayer is configured to spray substantially transversely over the outward facing side of the filter surface.


News Article | May 9, 2017
Site: www.topix.com

Commuters in the San Francisco area can feel even better about taking public transport to lower their carbon footprints , as the Bay Area's Rapid Transit system will soon be powered by 100 percent renewable energy . Days ago, the BART board of directors passed an electrical portfolio policy that requires 50 percent of the organization's power to be sourced from renewables by 2025. Start the conversation, or Read more at Inhabitat.


SALT LAKE CITY, May 12, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced new data demonstrating the utility of the Prolaris® test to accurately predict the 10-year risk of metastases in men treated for prostate cancer. The data are being presented tomorrow at the American Urological Association (AUA) 2017 Annual Meeting in Boston, Mass. This study was conducted in collaboration with Stephen Bardot, M.D., and colleagues at Ochsner Clinic in New Orleans, Louisiana.  A total of 767 men with localized prostate cancer were evaluated using the Prolaris test plus CAPRA (i.e., clinical features) to predict the risk of metastatic disease up to 10 years following diagnosis.  Approximately 40 percent of the patients in the study were African Americans (AA).  Among all 767 patients 39 men, or 5.1 percent, developed metastases and among the 646 men who received definitive therapy (e.g., surgery, radiation, radiation and hormones) 28 men, or 4.3 percent, developed metastatic disease. The results showed that the Prolaris test was a significant predictor of metastatic disease with a nearly 3-fold increased risk for each one-unit increase on the Prolaris test score (Hazard Ratio per unit score = 2.76; P = 2.8x10-11).  Importantly, there was no difference in predictive performance between races (p=0.20) or treatment groups (p=0.09).  When combined with CAPRA the Prolaris test was highly predictive of metastatic disease (HR for combined clinical risk (CCR) = 3.86; p= 2.8x10-23).  Contrary to expectations, this large study found no evidence that AA men have more aggressive prostate cancer than non-AA men after accounting for all molecular and clinical information. “Our study confirmed that the Prolaris test significantly predicts which men are likely to develop metastatic disease, regardless of race, risk group or treatment approach,” said Dr. Bardot.  “This study also included a large group of AA men which have historically been underrepresented in clinical outcomes studies.  This study demonstrated that Prolaris provided more accurate precision in providing prognosis in African American and non-African Americans equally.” The findings from the current study are consistent with the findings of an earlier study that demonstrated the ability of the Prolaris test in predicting cancer progression, as measured by both biochemical recurrence and metastatic disease, after radical prostatectomy. That prior study found that patients with a high Prolaris test score had a six-fold higher risk of developing metastases compared to low risk patients. Based on the strength of the data from these two outcomes studies, Myriad has added risk of metastases to the Prolaris test report for clinicians, making Prolaris the first and only genetic test to provide this endpoint as validated by two outcomes studies. “Myriad Genetics is committed to innovation and being the leader in genetic testing for men diagnosed with prostate cancer,” said Michael Brawer, M.D., senior vice president of Medical Affairs, Myriad Genetic Laboratories.  “We have multiple outcome studies that show the ability of Prolaris to predict the 10-year risk of prostate cancer specific mortality, and we now have two studies that predict the risk that treatment will fail and men will end up with metastatic disease.  We are excited to provide all of this relevant information in a single test report for clinicians.” Follow Myriad on Twitter via @MyriadGenetics and stay informed about symposium news and updates by using the hashtag #AUA17.  Details of the presentation at AUA follow. Featured Presentation Title: Evaluating the Prognostic Utility of the CCP Score for Predicting Prostate Cancer Aggressiveness in African American Men Presenter: Steven Bardot, M.D., Ochsner Medical Center Date: Saturday, May 13, 2017: 7:00-9:00 a.m. ET. Location: Moderated Poster MP28-19; Room 253AB. About Prolaris® Prolaris is a novel 46-gene RNA-expression test that directly measures tumor cell growth characteristics for stratifying the risk of disease-specific mortality in patients with prostate cancer. Prolaris provides a quantitative measure of the RNA expression levels of genes involved in the progression of tumor growth.  Low gene expression is associated with a low risk of disease-specific mortality in men who may be candidates for active surveillance and high gene expression is associated with a higher risk of disease-specific mortality in patients who may benefit from additional therapy.  For more information visit: www.prolaris.com. About Myriad Genetics Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics.  Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs.  Myriad is focused on three strategic imperatives:  transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets.  For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com. Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, EndoPredict, Vectra, GeneSight and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G. Safe Harbor Statement        This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to Prolaris data being presented at the at the American Urological Association’s 2017 Annual Meeting being held May 12-16, 2017 in Boston, Mass.; the utility of the Prolaris® test to accurately predict the 10-year risk of metastases in men treated for prostate cancer; the ability of the Prolaris test to significantly predict which men are likely to develop metastatic disease, regardless of race, risk group or treatment approach; and the Company's strategic directives under the caption "About Myriad Genetics."  These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described or implied in the forward-looking statements. These risks include, but are not limited to: the risk that sales and profit margins of our existing molecular diagnostic tests and pharmaceutical and clinical services may decline or will not continue to increase at historical rates; risks related to our ability to transition from our existing product portfolio to our new tests; risks related to changes in the governmental or private insurers' reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services tests and any future tests are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities; risks related to public concern over our genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire, including but not limited to our acquisition of Assurex, Sividon and the Clinic; risks related to our projections about the potential market opportunity for our products; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements;  the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our Annual report on Form 10-K for the fiscal year ended June 30, 2016, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.


News Article | May 12, 2017
Site: www.prnewswire.com

"This is the 23rd year of the Bay Area's Bike to Work Day, and I'm proud to say that MTC has been a sponsor for all of those years," said MTC Chair Jake Mackenzie, who biked his way to Sonoma Mountain Village to welcome a Zero Waste symposium to Rohnert Park, where he serves as mayor. "We do it because cycling is a key strategy for keeping our cities livable and reducing greenhouse gas emissions. We're really pleased to see cities all around the Bay joining with us in investing in bike infrastructure, and making their streets bike-friendly." In addition to sponsoring the yearly Bike to Work Day event, MTC provides $20 million a year in discretionary funding for bicycle projects around the nine-county San Francisco Bay Area. Local politicians demonstrated their support of the festivities by joining commuters on their own two wheels and helping at energizer stations. MTC Commissioners who participated in the bike commuting celebration include Rohnert Park Mayor and MTC Chair Jake Mackenzie; Alameda County Supervisor Scott Haggerty, who is also MTC's vice chair; Marin County Supervisor Damon Connolly; Union City Mayor Carol Dutra-Vernaci; BART Board Director Nicholas Josefowitz; San Francisco Supervisor Jane Kim; San Jose Mayor Sam Liccardo; Napa County Supervisor Alfredo Pedroza; Oakland Mayor Libby Schaaf; Solano County Supervisor Jim Spering; and Orinda Councilmember Amy Worth. Additional elected officials included Belmont City Councilmember Davina Hurt; Benicia Mayor Elizabeth Patterson; Berkeley Mayor Jesse Arreguin; Calistoga Mayor Chris Canning; Dublin City Councilmembers Arun Goel and Melissa Hernandez; Fairfield Mayor Harry Price; Napa County Supervisors Ryan Gregor and Brad Wagenknecht; Oakland Councilmembers Abel Guillen, Dan Kalb, Annie Campbell-Washington, Noel Gallo, Desley Brooks, Larry Reid, Rebecca Kaplan and Lynette Gibson-McElhaney; Redwood City Councilmember Shelly Masur; San Francisco Mayor Ed Lee; San Francisco Supervisors London Breed and Katy Tang; San Leandro Councilmember Ed Hernandez; San Leandro Vice Mayor Lee Thomas; San Mateo County Supervisor Dave Pine; San Ramon Mayor Bill Clarkson; Santa Clara County Supervisor Ken Yeager; Sebastopol City Councilmember Sarah Glade Gurney; and Vacaville Mayor Len Augustine. Other notable regional leaders included Menlo Park Complete Streets Committee members Lydia Lee and Betsy Nash; Napa Valley Transportation Authority Executive Director Kate Miller; Redwood City Complete Streets Committee Chair Matthew Self; Redwood City Transportation Coordinator Jessica Manzi; San Francisco Municipal Transportation Agency Director Ed Reiskin; San Francisco County Transportation Authority Executive Director Tilly Chang; San Francisco Public Works Director Mohammed Nuru; San Francisco Assessor-Recorder Carmen Chu; San Francisco Fire Chief Joanne Hayes-White; San Francisco Municipal Transportation Authority Board Chair Cheryl Brinkman; and VTA General Manager Nuria Fernandez. "Exercise is very important, we all need more of it but in many cases our busy schedules seem to get in the way," said Dr. Todd Weitzenberg, Sport Medicine Specialist at Kaiser Permanente Santa Rosa. "One way to add exercise into our daily lives is by biking to work, as so many people throughout the Bay Area did today. In addition to the health benefits, cycling is a lot of fun and can be enjoyed with friends and family." Photographs from today's event can be found here. Bike to Work Day is the largest event in the Bay Area's celebration of National Bike Month in May, but there are many other events and activities held during the month. Team Bike Challenge is a friendly competition that encourages participants and companies to ride individually and collectively to earn bragging rights as the best in each county and across the region. In 2016, 2,519 cyclists riding on 1,827 teams for 535 companies rode almost 374,100 miles — saving close to 374,100 pounds of CO and burning close to 16,085,500 million calories. Presented by MTC, 511 and Kaiser Permanente, Bay Area Bike to Work Day encourages local residents to try commuting on two wheels for the first time and celebrates those who bike to work regularly. In addition to MTC (the transportation planning, financing and coordinating agency for the nine-county San Francisco Bay Area), 511 (the region's traveler information system) and Kaiser Permanente, Bike to Work Day 2017 receives regional support from the Bay Area Air Quality Management District (BAAQMD), Bay Area Rapid Transit (BART), Clear Channel Outdoor, and Clif Bar, as well as from many sponsors at the local level. Bike to Work Day's media sponsor is NBC Bay Area-KNTV/Telemundo 48. Prizes for the Bike Commuter of the Year winners were donated by the Association of Bay Area Governments (ABAG), Chipotle and Mike's Bikes. The event is made possible through the cooperation of thousands of volunteers, county congestion management agencies, local jurisdictions, local bicycling coalitions and MTC. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nearly-100000-cycle-to-work-on-bike-to-work-day-2017-300456918.html


Patent
Russell, Johnson, Bart and Petka | Date: 2012-11-21

A method for conducting secure transactions is disclosed, the method comprising receiving from a customer a customer identifier and a value for at least one prescribed personal data field different from the customer identifier; certifying that the value of the at least one prescribed personal data field is associated with the customer; and reducing the price of a deliverable by a prescribed discount in exchange for the value for the at least one prescribed personal data field. An apparatus for use in carrying out the comprises a biometric sensor configured to receive a biometric input; a memory configured to store a biometric template associated with a user, the memory configured to store a value associated with the user, the value being associated with a prescribed personal data field; and a processor coupled to the biometric sensor and the memory, the processor configured to authenticate a biometric input based on the biometric template, the processor configured to output to a receiving party associated with a deliverable the value associated with the user such that the receiving party reduces a price of the deliverable by a prescribed discount when the biometric input is authentic.


Vitolins M.Z.,BART
Journal of clinical oncology : official journal of the American Society of Clinical Oncology | Year: 2013

Hot flashes occur in approximately 80% of androgen-deprived men. Few intervention studies have been conducted to relieve hot flashes in men. Eligible androgen-deprived men were randomly assigned to one of four daily regimens (2 × 2 factorial design) for 12 weeks: milk protein powder and placebo pill, venlafaxine and milk protein powder, soy protein powder and placebo pill, or venlafaxine and soy protein powder. The primary end point was hot flash symptom severity score (HFSSS), defined as number of hot flashes times severity. The secondary end point was quality of life (QoL), assessed by using the Functional Assessment of Cancer Therapy-Prostate. In all, 120 men age 46 to 91 years participated. Most were white (78%) and overweight or obese (83%). Toxicity was minimal. Neither venlafaxine nor soy protein alone or in combination had a significant effect on HFSSS. Soy protein, but not venlafaxine, improved measures of QoL. In androgen-deprived men, neither venlafaxine nor soy proved effective in reducing hot flashes. Interventions that appear effective for decreasing hot flashes in women may not always turn out to be effective in men.


Patent
Bart | Date: 2016-05-16

A firearm safety system and method is described herein. The system may include a tracking system, a smart firearm and/or a smart magazine, and a smart tracking unit. The tracking system is in communication with satellites that monitor specific locations, a smart firearm and a portable electronic device. The tracking system includes an internal geographical database of specific monitored locations. The smart firearm includes a microprocessor and a receiver. The motor operates in response to a signal received, which may indicate that the firearm is approaching a no gun safety zone, whereby the signal causes the microprocessor to operate the automatic safety lock to prevent the apparatus from operating. The receiver monitors signals and receives location data from the satellites. The method of operating a smart firearm includes receiving a signal at the at least one receiver and responding to the signal by locking the automatic safety lock.

Loading BART collaborators
Loading BART collaborators